WellSky Corporation

Overview

WellSky Corporation (formerly Mediware Information Systems, founded 1980) is a healthcare technology company providing software, analytics, and services across post-acute care, specialty pharmacy, blood banking, and care coordination. Backed by TPG Capital since December 2016 with Leonard Green & Partners joining via a July 2020 recapitalization, WellSky has executed 15 acquisitions to assemble a platform spanning home health, hospice, specialty pharmacy (CareTend), blood/biotherapies management, and hospital-to-post-acute care coordination (CarePort).

The company generates over $800M in revenue (2024) with the CEO stating it will eclipse $1B within 12-24 months. EBITDA exceeds $250M (2022 figure) with 30%+ margins. Scale metrics: 20,000+ client sites, 2,500 hospitals and ACOs, 130,000+ post-discharge providers, 54 million+ referrals per year, approximately 75% of the U.S. blood supply managed on WellSky systems, 33 million+ infusion prescriptions annually, and 10,000+ daily home infusion users.

Services & Capabilities

CareTend Specialty Pharmacy

WellSky’s flagship pharma-relevant platform and the leading specialty pharmacy EMR:

• Workflow Management: Prescription intake, clinical review, dispensing queues, patient care management
• Revenue Cycle: Drug contract management, automated billing, reimbursement optimization
• Compliance: Accreditation support, regulatory reporting, e-document storage
• Real-Time BI: Embedded analytics and reporting dashboards
• Home Infusion: Specialized workflows for home infusion pharmacy, compounded drugs, DME
• Migration: ~70% of clients migrated from legacy CPR+ platform to CareTend

CarePort Care Coordination

Acquired for $1.35B, CarePort is the dominant hospital-to-post-acute referral network:

• Scale: 2,500 hospitals, 130,000+ post-discharge providers, 54M referrals/year
• Market Share: Handles 30%+ of U.S. hospital discharges
• SkySense AI: Referral intake AI launched January 2026; CarePort-specific referral intake AI launched March 2026
• Use Case: Enables hospitals to identify optimal post-acute providers (home health, SNF, hospice, SP) based on quality, capacity, and patient needs

Blood Banking & Biotherapies

• FDA 510(k) Cleared: Regulatory-grade blood management software
• Market Position: Manages approximately 75% of the U.S. blood supply
• Cell Therapy: CAR-T and cell therapy chain-of-custody and tracking
• Transfusion Medicine: Hospital blood bank management, donor management, component production

Home Health & Hospice

• Kinnser Heritage: Industry-leading home health/hospice EMR (acquired)
• CareInsights AI: Predictive analytics for patient outcomes, hospitalization risk
• Clinical Documentation: OASIS assessment, care planning, scheduling, billing

Data & Analytics

• WellSky Insights: Cross-platform analytics leveraging 54M+ referral records
• Trella Health Partnership: Post-acute market intelligence covering 255M+ lives
• SkySense AI: AI platform spanning referral intake, predictive analytics, and operational optimization

Competitive Position

WellSky’s competitive position varies by segment:

Specialty Pharmacy (CareTend):

• Primary competitors: Brightree (ResMed), QS/1 (Transaction Data Systems), PioneerRx
• CareTend is the only single-vendor solution connecting infusion prescription management + post-acute referral network + blood/biologic management
• Home infusion focus differentiates from pharmacy-only competitors

Care Coordination (CarePort):

• Near-monopoly position with 30%+ of U.S. hospital discharges
• Competitors: Enso (formerly Collective Medical), Bamboo Health, but none match referral volume

Blood Banking:

• Dominant position (~75% U.S. blood supply) with high switching costs (FDA-regulated)
• Limited competition: Haemonetics, Mediware legacy

Competitive Moat

• Network Effects: 54M annual referrals create data density that improves matching algorithms and attracts more participants
• Blood Banking Franchise: FDA-regulated, 75% market share with extreme switching costs
• Pharmacy Specificity: CareTend purpose-built for specialty/infusion vs. general pharmacy management systems
• Cross-Sell Density: 15 acquisitions create multiple product entry points within existing health system clients

Recent Developments

• March 2026: Launched SkySense AI for CarePort referral intake automation
• January 2026: Launched SkySense AI for general referral intake
• October 2024: Acquired Bonafide to expand DME/HME capabilities
• 2024: 400+ hospitals adopted CarePort; continued CareTend migration from CPR+
• February 2025: Launched Patient Panel dashboard for clinical workflow optimization
• 2025: Published Evolution of Care Report on AI/predictive analytics trends in post-acute care

M&A History (15 Acquisitions Since 2016)

Key acquisitions include:

Acquisition	Year	Strategic Value
Kinnser Software	2017	Home health/hospice EMR market leadership
ClearCare	2019	Personal care/home care agency management
CarePort Health	2020	Hospital-to-post-acute referral ($1.35B)
Experience Care	2021	Senior living/long-term care
Corridor	2022	Revenue cycle for home health
Bonafide	2024	DME/HME management

Client & Partner Ecosystem

• Health System Clients: 2,500+ hospitals and ACOs; largest U.S. health systems
• Post-Acute Providers: 130,000+ (home health, hospice, SNF, specialty pharmacy, DME)
• Specialty Pharmacy Clients: 10,000+ daily home infusion users; 33M+ infusion Rx annually
• Blood Centers: Serving facilities managing ~75% of U.S. blood supply
• Partners: Trella Health (post-acute intelligence, 255M+ lives), Enclara Pharmacia (hospice PBM), Citus Health, McKesson, IQVIA, Surescripts, Change Healthcare, Panoramic Health

Cross-References

• CareTend competes in Pharmacy Technology & Workflow
• Blood banking and CareTend infusion connect to Infusion & Clinical Services
• CarePort and WellSky Insights connect to Data Analytics & Real-World Evidence
• Trella Health — strategic data partnership
• Brightree — competitor in home infusion/DME software

Technology Platform

• CareTend: Specialty pharmacy EMR (successor to CPR+)
• CarePort Connect: Hospital-to-post-acute referral and care coordination platform
• SkySense AI: AI/ML platform for referral intake, predictive analytics, operational optimization
• CareInsights AI: Predictive analytics for home health patient outcomes
• WellSky Insights: Cross-platform analytics and business intelligence
• Blood Management Suite: FDA 510(k) cleared blood banking, donor management, cell therapy tracking
• Patient Panel: Clinical workflow dashboard (launched Feb 2025)

Sources

• WellSky Homepage
• WellSky About
• WellSky History
• WellSky Specialty Pharmacy
• WellSky Partners
• Hospice News - TPG/Leonard Green
• CB Insights
• raw/research/wellsky.pplx.md